18f-mni-659
Small moleculeexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2013 (NCT02061722)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f mni-659
- 18f mni-659
- 18f-mni-659
- 18f-mni-659
- 18f-mni-659
- 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione
- mni-659
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02956148 | Early Phase 1 (Phase 1) | Jun 1, 2015 | CHDI Foundation, Inc., Karolinska Institute |
| NCT02061722 | Early Phase 1 (Phase 1) | Jan 1, 2013 | CHDI Foundation, Inc., University of Ulm |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CHDI Foundation, Inc. | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Ulm | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1